1. Home
  2. DMRC vs NYXH Comparison

DMRC vs NYXH Comparison

Compare DMRC & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digimarc Corporation

DMRC

Digimarc Corporation

HOLD

Current Price

$9.11

Market Cap

158.2M

Sector

Technology

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$4.87

Market Cap

188.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DMRC
NYXH
Founded
2008
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
EDP Services
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
158.2M
188.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
DMRC
NYXH
Price
$9.11
$4.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$20.00
$12.67
AVG Volume (30 Days)
135.8K
52.4K
Earning Date
10-30-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$33,663,000.00
$6,616,215.00
Revenue This Year
N/A
$79.25
Revenue Next Year
$7.63
$297.08
P/E Ratio
N/A
N/A
Revenue Growth
N/A
10.96
52 Week Low
$6.35
$4.35
52 Week High
$48.32
$11.87

Technical Indicators

Market Signals
Indicator
DMRC
NYXH
Relative Strength Index (RSI) 57.72 47.87
Support Level $7.57 $4.75
Resistance Level $9.64 $5.00
Average True Range (ATR) 0.54 0.23
MACD 0.24 0.05
Stochastic Oscillator 83.89 71.43

Price Performance

Historical Comparison
DMRC
NYXH

About DMRC Digimarc Corporation

Digimarc Corp is engaged in digital watermarking technologies. The Digimarc Illuminate platform is a distinctive software as a service (SaaS) cloud-based platform for digital connectivity that provides the tools for the application of digital watermarks and dynamic Quick Response (QR) codes, software (digital twins) that enables various systems and devices to interact with those data carriers and a centralized platform for capturing insights about digital interactions and automating activities based on that information. The company generates revenue through commercial and government applications of its technology. The company derives its revenue from software development services, subscriptions for products and related services, and licensing of patents.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: